Literature DB >> 2450768

Inhibition and recovery of retrograde axoplasmic transport in rat optic nerve during and after elevated IOP in vivo.

J O Johansson1.   

Abstract

Horseradish peroxidase (HRP) injected into one lateral geniculate nucleus of male inbred PVG/Mol hooded rats is taken up by terminals of the optic nerve and transported retrogradely towards the opposite retina. One hr after injection, the eyes were cannulated and set at an intraocular pressure (IOP) of either 35 mmHg or 15 mmHg. The IOP were set for 4 hr at which time the trial was terminated and retinal HRP content measured. It was found that in eyes set at 35 mmHg (18 eyes) the axoplasmic transport was partially blocked compared with that in eyes set at 15 mmHg (10 eyes), absorbances were 0.034 +/- 0.003 (S.E.) and 0.044 +/- 0.003 (S.E.), respectively, P less than 0.05. In a third group of eyes (nine eyes) set at 50 mmHg for 2 hr (beginning 1 hr after the intrageniculate injection), succeeded by another 2 hr of 15 mmHg IOP, there was no statistically significant difference in retinal HRP content compared to that in eyes set at 15 mmHg throughout, absorbances were 0.040 +/- 0.006 and 0.044 +/- 0.003, respectively. Two hr of 50 mmHg IOP blocks the axonal transport in the rat optic nerve (Johansson, 1986a). The result shows that also moderately increased IOP blocks axonal transport in the rat optic nerve. It also shows the presence of a rapid recovery when the pressure is normalized. A direct mechanical factor underlying axonal transport blockage is proposed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2450768     DOI: 10.1016/s0014-4835(88)80079-4

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  23 in total

1.  Retrobulbar pressures measured during surgical decompression of the orbit.

Authors:  A J Otto; L Koornneef; M P Mourits; L Deen-van Leeuwen
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

Review 2.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

3.  Recovery from conduction failure in optic axons spared by lesions in the rat.

Authors:  A P Foerster
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

Review 4.  Critical pathogenic events underlying progression of neurodegeneration in glaucoma.

Authors:  David J Calkins
Journal:  Prog Retin Eye Res       Date:  2012-08-01       Impact factor: 21.198

Review 5.  Targets of Neuroprotection in Glaucoma.

Authors:  Shaoqing He; Dorota L Stankowska; Dorette Z Ellis; Raghu R Krishnamoorthy; Thomas Yorio
Journal:  J Ocul Pharmacol Ther       Date:  2017-08-18       Impact factor: 2.671

6.  Evaluation of retinal nerve fiber layer thickness and axonal transport 1 and 2 weeks after 8 hours of acute intraocular pressure elevation in rats.

Authors:  Carla J Abbott; Tiffany E Choe; Theresa A Lusardi; Claude F Burgoyne; Lin Wang; Brad Fortune
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-04       Impact factor: 4.799

Review 7.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration.

Authors:  Selva Baltan; Denise M Inman; Camelia A Danilov; Richard S Morrison; David J Calkins; Philip J Horner
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

9.  Morphology of astrocytes in a glaucomatous optic nerve.

Authors:  Ming Lye-Barthel; Daniel Sun; Tatjana C Jakobs
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

10.  The distributions of mitochondria and sodium channels reflect the specific energy requirements and conduction properties of the human optic nerve head.

Authors:  M J Barron; P Griffiths; D M Turnbull; D Bates; P Nichols
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.